Acrivon Therapeutics Conference Call Summary Company Overview - **Company**: Acrivon Therapeutics (NasdaqGM:ACRV) - **Focus**: Development of precision oncology therapies utilizing the AP3 generative phosphoproteomics platform Key Industry Insights - **Industry**: Oncology, specifically targeting endometrial cancer and other solid tumors - **Market Need**: Significant unmet need in treating relapsed serous endometrial cancer, which accounts for approximately 40% of all endometrial cancer deaths, translating to about 20,000 deaths annually in the U.S. and EU combined [15][16] Core Points and Arguments 1. **AP3 Platform**: Acrivon's AP3 platform allows for unbiased identification and quantification of drug effects on disease-causing signaling pathways, enhancing drug discovery and development [4][5] 2. **Pipeline Overview**: The pipeline includes: - ACR368: A potent selective CHK1/2 inhibitor with promising clinical data - ACR2316: A dual WEE1/PKMYT1 inhibitor designed to overcome resistance mechanisms - ACR6840: A new candidate targeting CDK11, with potential first-in-class status [6][29] 3. **Clinical Data for ACR368**: - Overall response rate of 39% in biomarker-positive endometrial cancer patients treated with ACR368 monotherapy [11] - Disease control rate of over 80% in the same population [11] - Notable response rates of 67% in serous tumors, indicating a strong potential for this subgroup [13] 4. **Regulatory Pathway**: A phase 3 confirmatory trial protocol for ACR368 has been submitted to the FDA, aiming to improve progression-free and overall survival in advanced endometrial cancer [18][20] 5. **Combination Therapy Potential**: ACR368 shows strong synergy with anti-PD-L1 therapies, which may enhance treatment efficacy [9][34] 6. **Safety Profile**: ACR368 has a favorable tolerability profile, primarily associated with transient hematological adverse events, with no significant non-hematological adverse events reported [9][40] Additional Important Insights - **Market Opportunity**: The prevalence of relapsed serous endometrial cancer is estimated at 55,000-60,000 patients, with a significant portion progressing to second-line therapy, highlighting the potential market for ACR368 [15][16] - **Emerging Candidates**: ACR6840 is positioned as a potential first-in-class agent targeting CDK11, with promising preclinical anti-tumor activity and a planned IND submission in Q4 2026 [29][31] - **Dosing Regimens**: ACR2316 has established two-weekly oral dosing regimens, showing activity in heavily pretreated patients with aggressive cancers like small cell lung cancer and squamous non-small cell lung cancer [34][35] Conclusion Acrivon Therapeutics is advancing its innovative oncology pipeline with a focus on precision medicine, particularly in addressing the unmet needs in endometrial cancer. The promising clinical data for ACR368 and the strategic regulatory submissions position the company favorably within the oncology landscape.

Core Insights - Acrivon Therapeutics is hosting a virtual R&D event on March 25, 2025, to showcase its drug discovery capabilities and updates on its clinical studies [2][3] - The company utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform for developing precision oncology medicines tailored to patients' tumor sensitivities [4][5] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company focused on precision oncology, employing the AP3 platform to discover and develop drug candidates [4] - The AP3 platform generates extensive quantitative data for pathway-based drug design and response prediction, facilitating rational drug discovery and the identification of effective drug combinations [4][7] Clinical Development - Acrivon's lead candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial for multiple tumor types [4] - The FDA has granted Fast Track designation for ACR-368 as a monotherapy for patients with platinum-resistant ovarian or endometrial cancer, based on OncoSignature-predicted sensitivity [4] - Acrivon is also developing ACR-2316, a selective WEE1/PKMYT1 inhibitor, aimed at enhancing single-agent activity through the activation of key cell cycle proteins [5] Key Opinion Leaders - The event will feature presentations from notable experts in gynecologic oncology, including Dr. Mansoor Raza Mirza, Dr. Robert L. Coleman, and Dr. Jesper Olsen, who will provide insights into endometrial cancer [6] Future Directions - Acrivon is advancing its proprietary AP3 Interactome platform for comprehensive analyses of drug profiling data, which supports its ongoing research programs [7]

Core Insights - Acrivon Therapeutics is hosting a virtual R&D event on March 25, 2025, to showcase its drug discovery capabilities and provide updates on its clinical studies [1][2] - The company utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform for developing precision oncology medicines tailored to patients' tumor sensitivities [3][4] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company focused on precision oncology, employing the AP3 platform to discover and develop drug candidates [3] - The AP3 platform generates extensive quantitative data for pathway-based drug design and response prediction, facilitating rational drug discovery and the identification of effective drug combinations [3][4] Clinical Development - Acrivon's lead candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial for multiple tumor types [3] - ACR-368 has received Fast Track designation from the FDA for use as monotherapy in patients with platinum-resistant ovarian or endometrial cancer [3] - The company is also developing ACR-2316, a selective WEE1/PKMYT1 inhibitor, aimed at enhancing single-agent activity through the activation of key cell cycle proteins [4] Key Opinion Leaders - The event will feature presentations from notable experts in gynecologic oncology, including Dr. Mansoor Raza Mirza, Dr. Robert L. Coleman, and Dr. Jesper Olsen, who will discuss the implications of Acrivon's research [5]